The Empirical Limit: When N=1 Meets the FDA

The statistical paradox

Traditional medicine is built on the foundation of large cohort studies: hundreds or thousands of participants, randomised into treatment and control groups, and a search for statistically significant differences. This approach has served us well, establishing clear standards for evidence and enabling countless life-saving treatments.

But what happens when medicine becomes truly personalised? When a treatment is optimised not just for a disease, but for a specific individual's genetic markers, microbiome composition, lifestyle factors and medical history? Suddenly our N of thousands becomes an N of 1.

The alternative-medicine parallel

Here it gets interesting — and uncomfortable for many in the scientific establishment. Alternative medicine has always operated in the N=1 space: the homeopath who spends two hours on a complete symptom picture; the TCM practitioner who designs a unique herbal formula per individual; the functional-medicine doctor who orders extensive testing to map each patient's biochemistry.

These practices have long been criticised for relying on anecdotal evidence. Yet as mainstream medicine moves toward personalisation, we find ourselves on remarkably similar terrain. The old critique — lack of statistical power — becomes a fundamental challenge for personalised medicine.

The FDA's dilemma

Regulatory agencies like the FDA are built on the assumption of generalisable evidence for safety and efficacy. A drug works for a population or it doesn't. Personalised treatments challenge this binary frame.

Consider CAR-T-cell therapy: a patient's own immune cells are genetically modified to fight their specific cancer. Each treatment is, by definition, unique. How do we apply traditional RCT methodology to interventions that are individualised by design?

Belief and context as mechanisms

If treatments are becoming increasingly personalised, we must also consider the personal factors that influence therapeutic outcomes: expectation, the relationship with the provider, the ritual of administration. These are not confounding variables to be controlled. They are integral parts of the therapeutic system.

A treatment perfectly tailored to your genetic markers, administered by a doctor you trust, in a context that reinforces your belief in its efficacy — is this the pinnacle of scientific medicine, or the ultimate placebo? The empirical limit suggests this distinction may dissolve.

New evidence models

If classical RCTs no longer suffice, what then?

• N-of-1 trials — rigorous studies within single patients, using multiple crossover periods to establish individual efficacy.
• Real-world evidence — aggregating outcomes from clinical practice to identify patterns in personalised treatments.
• Digital twins — computational patient models that predict treatment responses.
• Adaptive trial designs — studies that evolve as data accumulates, personalising as they progress.

Implications for practice

For practitioners, the empirical limit demands new competencies:

• Interpreting individual biological data
• Recognising patterns within single patients over time
• Understanding the role of context and expectation in therapeutic outcomes
• Navigating uncertainty when no precedent exists

This is not a return to pre-scientific medicine. It is an evolution toward what we might call precision empiricism — maintaining rigorous standards while acknowledging the irreducible individuality of every therapeutic encounter.

Conclusion

The empirical limit reveals a fundamental tension in modern medicine. We want treatments that are both universally validated and individually optimised. We want the certainty of large trials and the specificity of personalised care. We want to eliminate placebo effects and at the same time harness the power of expectation.

The resolution lies not in choosing sides but in developing frameworks that hold these tensions productively. The empirical limit isn't an obstacle to overcome — it's a horizon that expands our understanding of what medicine can be.